We are live on
!
Find out more
LCP
Lamond Capital Partners Portfolio holdings
AUM
$14.3M
1-Year Est. Return
30.74%
This Fund
S&P 500
This Quarter
Est. Return
-21.94%
1 Year Est. Return
-30.74%
3 Year Est. Return
+54.28%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$134M
AUM Growth
+$35.1M
(+36%)
Cap. Flow
-$1.5M
Cap. Flow
% of AUM
-1.12%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
18
New
7
Increased
3
Reduced
–
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$13.4M |
| 2 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$13.3M |
| 3 |
CY
Cypress Semiconductor
CY
|
+$11.5M |
| 4 |
Ocular Therapeutix
OCUL
|
+$10.5M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$7.91M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
|
+$14.1M |
| 2 |
HP
HPQ
|
+$10.1M |
| 3 |
VMEM
VIOLIN MEMORY, INC.
VMEM
|
+$9.64M |
| 4 |
HOS
Hornbeck Offshore Services, Inc.
HOS
|
+$7.24M |
| 5 |
KITE
Kite Pharma, Inc.
KITE
|
+$6.64M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 51.12% |
| 2 | Miscellaneous | 41.87% |
| 3 | Technology | 7.01% |
| 4 | Industrials | 0% |
Similar funds
HCM
PPF
PM
TSU
RCMC
SCA
GFWEV
USG2
Lamond Capital Partners's Q3 2015 Portfolio in Review
As of Q3 2015, Lamond Capital Partners held 18 positions worth $134M, up 36% from $98.5M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Lamond Capital Partners's Q3 2015 filing shows 7 new, 3 increased and 8 closed positions. Its largest new stake was BioMarin Pharmaceuticals: 100,000 shares worth $10.5M. The largest sale was Sio Gene Therapies Inc. Common Stock, an estimated $14.1M.
By sector, the portfolio is most concentrated in Healthcare at 51% of assets, down from 66% a quarter earlier, followed by Miscellaneous and Technology.
- Lamond Capital Partners's largest Q3 2015 buy was BioMarin Pharmaceuticals: 100,000 shares worth $10.5M.
- Lamond Capital Partners added most to Ocular Therapeutix in Q3 2015, an estimated $10.5M increase.
- Lamond Capital Partners fully exited Sio Gene Therapies Inc. Common Stock in Q3 2015, selling an estimated $14.1M.
- Lamond Capital Partners's ten largest holdings make up 100% of its $134M portfolio in Q3 2015.
- Lamond Capital Partners opened 7 new positions and closed 8 in Q3 2015.
- Lamond Capital Partners's portfolio value rose 36% quarter-over-quarter to $134M.
Based on Lamond Capital Partners's 13F filing for Q3 2015, filed 9 Nov 2015.